title: Interferon alpha-2b therapy in chronic hepatitis delta.
abstract: BACKGROUND
  Approximately 5% of hepatitis B virus (HBV) carriers are coinfected with hepatitis D virus (HDV). HBV/HDV coinfection is a major cause of cirrhosis and end stage liver disease in chronic HBsAg carriers. The only approved therapy for chronic hepatitis delta is interferon alpha (IFN α) in either pegylated or conventional forms. Although higher doses and longer durations of IFN α therapy in HBV/HDV coinfected patients are currently applied, yet treatment response is low.
  
  
  OBJECTIVE
  We aimed to determine the efficacy of IFN α-2b therapy in patients with HBV/HDV coinfection.
  
  
  METHODS
  In this cross sectional study, 20 HBsAg carriers with positive Anti-HDVAb and RT-PCR for HDV RNA were recruited and treated for three year duration with 5 million units (MU) of IFN α-2b, three times weekly or one year with 5 MU of IFN α-2b daily. Sustained virological response (SVR) was defined as a negative qualitative HDV RT-PCR, 6 months after treatment cessation.
  
  
  RESULTS
  Overall, 3 (15%) subjects achieved SVR, 10 cases (50%) relapsed after treatment cessation and 7 (35%) patients did not clear HDV during the treatment.
  
  
  CONCLUSIONS
  HDV coinfection with HBV had very low response rate to high doses and long durations of IFN α-2b therapy.
authors.affiliation: Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran ; Middle East Liver Disease (MELD) Center, Tehran, IR Iran.
authors.forename: Maryam
authors.initials: M
authors.lastname: Keshvari
authors.affiliation: Middle East Liver Disease (MELD) Center, Tehran, IR Iran.
authors.forename: Seyed Moayed
authors.initials: SM
authors.lastname: Alavian
authors.affiliation: Middle East Liver Disease (MELD) Center, Tehran, IR Iran.
authors.forename: Heidar
authors.initials: H
authors.lastname: Sharafi
authors.affiliation: Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran.
authors.forename: Gharib
authors.initials: G
authors.lastname: Karimi
authors.affiliation: Department of Biostatistics, School of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Gholami Fesharaki
keywords: Hepatitis D; Interferon-alpha; Iran
references.citation: Antivir Ther. 2012;17(6):1029-37
references.pmid: 22892440
references.citation: Antivir Ther. 2013;18(4):561-6
references.pmid: 22976528
references.citation: J Viral Hepat. 2010 Nov;17(11):749-56
references.pmid: 20723036
references.citation: Gastroenterology. 2004 Jun;126(7):1740-9
references.pmid: 15188169
references.citation: N Engl J Med. 1994 Jan 13;330(2):88-94
references.pmid: 8259188
references.citation: J Hepatol. 1991;13 Suppl 1:S21-6
references.pmid: 1835731
references.citation: J Hepatol. 2010 Nov;53(5):834-40
references.pmid: 20800919
references.citation: Hepat Mon. 2011 Sep;11(9):731-5
references.pmid: 22235216
references.citation: J Clin Virol. 2010 Jan;47(1):97-9
references.pmid: 19914127
references.citation: Gut. 1977 Dec;18(12):997-1003
references.pmid: 75123
references.citation: J Res Med Sci. 2012 Oct;17(10):967-74
references.pmid: 23825999
references.citation: J Viral Hepat. 2008 Apr;15(4):314-21
references.pmid: 18307594
references.citation: J Med Virol. 1994 Dec;44(4):389-92
references.pmid: 7897369
references.citation: Liver. 1995 Feb;15(1):45-52
references.pmid: 7776857
references.citation: J Gastrointestin Liver Dis. 2011 Dec;20(4):377-82
references.pmid: 22187703
references.citation: N Engl J Med. 2011 Jan 27;364(4):322-31
references.pmid: 21268724
references.citation: Antivir Ther. 2005;10(6):721-6
references.pmid: 16218171
references.citation: Gastroenterology. 1999 Nov;117(5):1229-33
references.pmid: 10535887
references.citation: Antimicrob Agents Chemother. 2005 Mar;49(3):1135-8
references.pmid: 15728914
references.citation: J Med Virol. 2013 Sep;85(9):1513-7
references.pmid: 23852675
references.citation: Lancet. 2011 Jul 2;378(9785):73-85
references.pmid: 21511329
references.citation: Hepatology. 1994 Jun;19(6):1331-6
references.pmid: 8188163
references.citation: J Med Virol. 1993 Apr;39(4):292-6
references.pmid: 8492101
references.citation: J Viral Hepat. 2007 Nov;14 Suppl 1:58-63
references.pmid: 17958644
references.citation: J Viral Hepat. 2007 Nov;14(11):812-6
references.pmid: 17927618
references.citation: J Gastroenterol Hepatol. 2013 Sep;28(9):1521-5
references.pmid: 23574043
references.citation: Acta Virol. 2005;49(4):219-25
references.pmid: 16402678
references.citation: Hepatology. 1991 Jun;13(6):1052-6
references.pmid: 2050321
references.citation: Clin Res Hepatol Gastroenterol. 2013 Jun;37(3):e81-4
references.pmid: 23433964
references.citation: Hepatology. 2006 Sep;44(3):713-20
references.pmid: 16941685
references.citation: Methods Mol Med. 2004;95:85-93
references.pmid: 14982056
references.citation: Cochrane Database Syst Rev. 2011 Dec 07;(12):CD006002
references.pmid: 22161394
references.citation: World J Virol. 2012 Jun 12;1(3):71-8
references.pmid: 24175212